Status:
COMPLETED
Outcome of COVID-19 Patients After Extracorporeal Membrane Oxygenation for Acute Respiratory Distress Syndrome
Lead Sponsor:
Helsinki University Central Hospital
Conditions:
COVID-19
Extracorporeal Membrane Oxygenation Complication
Eligibility:
All Genders
Brief Summary
This study aims to investigate outcomes and predictors of outcome after extracorporeal membrane oxygenation (ECMO) therapy for severe acute respiratory syndrome (ARDS) in COVID-19 patients.
Detailed Description
We evaluated the outcome of adult patients with coronavirus disease 2019 (COVID-19)-related acute respiratory distress syndrome (ARDS) requiring the use of extracorporeal membrane oxygenation (ECMO).
Eligibility Criteria
Inclusion
- PCR-confirmed or suspected COVID-19 infection with ARDS who require any ECMO therapy
Exclusion
- None
Key Trial Info
Start Date :
March 1 2020
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
April 1 2021
Estimated Enrollment :
132 Patients enrolled
Trial Details
Trial ID
NCT04383678
Start Date
March 1 2020
End Date
April 1 2021
Last Update
April 20 2021
Active Locations (11)
Enter a location and click search to find clinical trials sorted by distance.
1
Helsinki University Hospital
Helsinki, Finland
2
University Hospital Jean Minjoz
Besançon, France
3
Nancy University Hospital
Nancy, France
4
Henri Mondon Unoversity Hospital
Paris, France